Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry

Abstract

In Poland, two proposed amendments to the reimbursement act are currently in preparation; these are likely to substantially change the pricing and reimbursement landscape for both drugs and medical devices. Proposed changes include: alignment of medical device reimbursement with that of pharmaceuticals; relaxing the strict reimbursement criteria for ultra-orphan drugs; establishment of an additional funding category for vaccines; introduction of compassionate use, and a simplified reimbursement pathway for well-established off-label indications; appreciation of manufacturers’ innovation and research and development efforts by creating a dedicated innovation budget; introduction of a mechanism preventing excessive parallel import; prolonged duration of reimbursement decisions and reimbursement lists; and increased flexibility in defining drug programmes. Both amendments are still at a draft stage and many aspects of the new regulations remain unclear. Nonetheless, the overall direction of some of the changes is already evident and warrants discussion due to their high expected impact on pharmaceutical and device manufacturers. Here we evaluate the main changes proposed to the reimbursement of drugs, vaccines, and medical devices, and examine the impact they are likely to have on market access and pharmaceutical industry in Poland.

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries

“…Several crucial changes are proposed in Polish reimbursement system. One of these changes aims to create an innovative reimbursement budget, which will provide funding for reimbursement of innovative products developed by manufacturers with research and development activities with considerable impact on the Polish economy ( 27 ). Therefore, the patient access in Poland to innovative therapies could be significantly improved.…”

Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years

“…• Products available for purchase in the pharmacy with a prescription (in the whole range of registered indications and purposes or in an indication specified by the clinical state); • Products used within chemotherapy (in the whole range of registered indications or in an indication specified by the clinical state); • Products covered within specific framework called drug programmes (Ustawa z dnia 12 maja, 2011; Badora et al, 2017).…”

“…Products covered within specific framework called drug programmes ( Ustawa z dnia 12 maja, 2011 ; Badora et al., 2017 ).…”